Trial · Interventional

CompletedPhase 3Registry data

Lanreotide In Polycystic Kidney Disease Study

Short name LIPS

NCTNCT02127437Other idLIPS-01

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Completed
Phase: Phase 3
Enrollment: 159 participants (actual)
Sponsor: Assistance Publique - Hôpitaux de Paris · Other
Design: Randomized · Double masking
Countries: 1 country
France
Start: 19 Sept 2014
Primary completion: 31 Jul 2019
Completion: 31 Jul 2019
First posted: 30 Apr 2014 (estimated)
Last update posted: 8 Apr 2026
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD

Timeline

1 trial · 1 completed

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2014201520162017201820192020

Ph 3
LIPS
NCT02127437
19 Sept 2014 to 31 Jul 2019

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

LIPS study (Lanreotide In Polycystic kidney disease Study) is a prospective randomized double blind placebo controlled study. The main objective is to prove that lanreotide, a somatostatin analog, is able to reduce the glomerular filtration rate decline over 3 years by at least 30%. Cardiovascular outcomes, blood pressure, quality of life and safety are among the secondary outcomes. The study, which will include 180 ADPKD patients, is scheduled to start in early 2014. An equal number of patients with chronic kidney disease stage 2 (90 patients with GFR 89 to 60 ml/mn/1.73 m2) and chronic kidney disease stage 3 (90 patients with GFR 59 to 30 ml/mn/1.73 m2) will be included. The primary endpoint (GFR decline) will be assessed by repeated measures, in the overall population as well as in the two GFR stratus.

Interventions

LanreotideDrug
salineDrug

Arms2

Experimental
A - treated group
Placebo comparator
B - control group

Primary outcomes1

Outcomes the sponsor listed as primary.

Glomerular filtration rate (GFR)
Time frame · month 36

Secondary outcomes(9)

Glomerular filtration rate (GFR)
Time frame · month 18
Glomerular filtration rate (GFR) decline
Time frame · month 36
Safety, tolerance
Time frame · month 36
Onset or worsening of hypertension
Time frame · month 18
Onset or worsening of hypertension
Time frame · month 36
Quality of life
Time frame · month 0
Registry description
SF-36, EQ5D
Quality of life
Time frame · month 18
Registry description
SF-36, EQ5D
Quality of life
Time frame · month 36
Registry description
SF-36, EQ5D
Cystic pain
Time frame · month 36

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2026

8 results

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Joly et al. 2026Kidney international

PMID 42320793DOI 10.1016/j.kint.2026.05.018PUB-42320793

Full text at the publisher8 results

Publisher page See results (8)

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

DerivedSt Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3. PMID 39356039

Eligibility

Who could join, as posted.

Sex: All
Age: from 18 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * autosomal dominant polycystic kidney disease (clinical, familial, imaging grounds) * measured GFR : 30 to 89 ml/mn/1.73m2 * age \> 18 * affiliated with health insurance * written informed consent Exclusion Criteria: * iohexol /iodine allergy * diabetes mellitus * other associated nephropathy suspected * evolutive or recent malignant disease ( in the previous 5 years) * cholelithiasis * uncontrolled hypertension (BP\>160/100 mmHg) * cardiac failure of grade III or IV according to the NYHA (New York Heart Association) classification * liver failure * psychiatric illness * pregnancy, lactation, lack of contraception * use of somatostatin analogs during the last 6 months

PepBank is a research reference. Talk to a doctor before you use any peptide.